Treatment of effluents from animal slaughterhouse industries is indispensable, standing out coagulation/flocculation/sedimentation processes. Bionanoparticles (BioNPs) (nanoparticles (NPs) functionalized with Moringa extracts (MO)) were studied as an alternative natural coagulant that would contribute to the microbial load reduction, without increasing the treated effluent toxicity. MO extracts were prepared with different salts, and then, in a kinetics study, different NPs mass and coagulant dosages were evaluated. In the best-defined conditions, microbial load, toxicity tests for the bioindicator Lactuca sativa, and NPs reuse evaluation were performed. Removals of 96.14% turbidity and 43.63% UV254nm were achieved when using 500 mg L-1 of BioNPs containing 60 mg of NPs for every 20 mL of MO extract prepared with 0.1 M CaCl2. The BioNPs with an external magnetic field also decreased the sedimentation time from 140 to 10 minutes compared to MO, and the process efficiency did not expressively decrease after reusing the recovered NPs. Through toxicity tests, BioNPs were not considered to leave residuals toxic to the Lactuca sativa in the treated effluent. Besides, the microbial load reduction was 97.33% for heterotrophic microorganisms and total mesophiles and 99.25% for molds/yeasts. Therefore, a satisfactory primary treatment was achieved, contributing to the sustainability of industries.Osteosarcoma (OS) is the most common primary malignant tumor in children and adolescents. Numerous studies have reported the importance of miRNA in OS. The purpose of this study is to predict potential biomarkers and new therapeutic targets for OS diagnosis and prognosis by analyzing miRNAs of OS plasma samples from the Gene Expression Omnibus (GEO) database.Data-sets were downloaded from the GEO and analyzed using R software.  https://www.selleckchem.com/products/AZD0530.html  Different expressions of miRNAs (DE-miRNAs) in plasma and mRNAs (DE-mRNAs) in OS patients were identified. Funrich was used to predict the transcription factors and target genes of miRNAs. By comparing the target mRNAs and DE-mRNAs, the intersection mRNAs were identified. The intersection mRNAs were imported to perform Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. MiRNA-mRNA regulatory network and a protein-protein interaction (PPI) network were constructed by using Cytoscape. Finally, a total of 164 DE-miRNAs, 256 DE-mRNAs, and 76 intersection mRNAs were identified. The top 10 TF of up- and down-regulated DE-miRNAs were also predicted. In addition, GO and KEGG analyses further revealed the intersection mRNAs. By constructing the miRNA-mRNA networks, we found miR-30d-5p, miR-17-5p, miR-98-5p, miR-301a-3p, and miR-30e-5p were the central hubs. COL1A1, COL1A2, MMP2, CDH11, COL4A1 etc. were predicted to be the key mRNA by constructing the PPI networks. Through a comprehensive bioinformatics analysis of miRNAs and mRNAs in OS, we explored the potential effective biomarkers and novel therapeutic targets for the diagnosis and prognosis of OS.Osteoarthritis (OA) is a common difficult-to-treat condition where the goal, in the absence of disease-modifying treatments, is to alleviate symptoms such as pain and loss of function. Acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids are common pharmacologic treatments for OA. Antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents under clinical investigation for the treatment of OA. This narrative review describes (and uses schematics to visualize) nociceptive signaling, chronification of pain, and the mechanisms of action (MOAs) of these different analgesics in the context of OA-related pain pathophysiology. Further, the varying levels of efficacy and safety of these agents observed in patients with OA is examined, based on an overview of published clinical data and/or treatment guidelines (when available), in the context of differences in their MOAs.The extracellular matrix (ECM) shows an essential effect during the occurrence and procession of human cancers. Type III collagen is a crucial component of ECM. Collagen Type III Alpha 1(COL3A1) is aberrantly expressed in a variety of cancers. Nevertheless, the role of COL3A1 in pan-cancer stays unidentified. In this study, we explored public databases, including Cancer Genome Atlas (TCGA), GTEx, GEPIA, cBioPortal, Oncommine, TIMER and GENEMANIA databases to identify the differential expression of COL3A1 in human cancer tissues and normal samples, followed by its prognostic value for patient survival. In addition, we explore the association between COL3A1 expression and immune infiltration. Further, we used the GeneMANIA database and Gene Set Enrichment Analysis (GSEA) to investigate Protein-Protein Interaction (PPI) and gene functional enrichment. Results show that COL3A1 expressed higher in tumor samples than in normal samples. Upregulation of COL3A1 is associated with a worse prognosis and a more advanced cancer stage. COL3A1 expression shows significant positive correlations with tumor-infiltrating immune cells (TIICs), including neutrophils, macrophages, CD8 + T cells, CD4 + T cells, dendritic cells, and B cells. Markers of TIICs demonstrated distinct patterns of COL3A1-related immune infiltration. COL3A1 expression was associated with ECM receptor interaction, regulation of actin cytoskeleton and focal adhesion pathways via GSEA analysis. In conclusion, COL3A1 may be a molecular biomarker for prognosis and immune infiltration in pan-cancer. It might act as a potential target for a new insight of human cancers management.
  To determine the accuracy of incremental Shuttle Walking Test (ISWT) in detecting exercise-induced bronchospasm (EIB) in adults with asthma and to verify whether there is an association of the drop in FEV
  between ISWT and cardiopulmonary exercise testing with constant-load CPET-CL.
 
  In this cross-sectional study 32 individuals with asthma performed two ISWTs, an incremental cardiopulmonary exercise test (CPET-I) and a constant-load cardiopulmonary exercise test (CPET-CL) with na interval of 48 h between tests. Spirometric measurements were obtained 5, 10, 15, 20 and 30 min after exercise; an FEV1 decline > 10% was considered EIB.
 
  Fifteen individuals had EIB in both tests [χ2 = 9.41; κ = 0.46 
   < 0.002 (95% CI 0.201-0.708)], with moderate agreement. There was a significant correlation between the greatest variation in the drop in FEV
  between the ISWT and the CPET-CL (
   = 0.48; 
   < 0.01). There was a significant difference for ventilation maintenance time above 40% of Maximum Voluntary Ventilation between the groups of positive EIB (
   = 0.